ASCENTAGE PHARMA GROUP INTERNATIONAL Initial Statement of Beneficial Ownership

ASCENTAGE PHARMA GROUP INTERNATIONAL director Marc E. Lippman reports his equity holdings in the company.

Accepted by SEC EDGAR 03/19/2026 - 11:16 AM EDT

(Moderate)

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

ASCENTAGE PHARMA GROUP INTERNATIONAL director Marc E. Lippman reports his equity holdings in the company. He holds 21,174 Ordinary Shares directly. He also holds options over 53,895 Ordinary Shares with an exercise price of $8.14 per share, based on conversion from HKD, expiring on November 26, 2035. These stock options vest in four equal annual installments on each of November 26, 2026, 2027, 2028 and 2029. In addition, he holds 63,895 restricted stock units, each representing one Ordinary Share, which vest on the same four annual dates and have no expiration date.

Insider Trade Summary

Holdings reported, no transactions

Holdings

Insider LIPPMAN MARC E

Role Director

Type	Security	Shares	Price	Value
Holding	Options	--	--	--
Holding	Restricted stock units	--	--	--
Holding	Ordinary Shares	--	--	--

Holdings: Options — 53,895 contracts (Direct); Restricted stock units — 63,895 contracts (Direct); Ordinary Shares — 21,174 shares (Direct)

Footnotes (3)

F1. The stock options vest in four equal increments on each of 11/26/2026, 2027, 2028 and 2029.
F2. The exercise price for the stock options is in HKD, and the exercise price included in the table represents conversion to USD based on the exchange rate on the date of grant.
F3. Each restricted stock unit (RSUs) represents a contingent right to receive one Ordinary Share of the Issuer upon vesting. The RSUs vest in four equal increments on each of 11/26/2026, 2027, 2028 and 2029 and have no expiration date.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What equity stake does Marc E. Lippman report in ASCENTAGE PHARMA (AAPG)?

Marc E. Lippman reports holding 21,174 Ordinary Shares of ASCENTAGE PHARMA directly. He also has options over 53,895 shares and 63,895 restricted stock units, giving him significant additional exposure to the company through future share-based awards.

What stock options does Marc E. Lippman hold in ASCENTAGE PHARMA (AAPG)?

He holds options over 53,895 Ordinary Shares with an exercise price of $8.14 per share. The options vest in four equal installments on November 26, 2026, 2027, 2028 and 2029, and they expire on November 26, 2035, providing long-term incentive alignment.

How are Marc E. Lippman’s restricted stock units in ASCENTAGE PHARMA (AAPG) structured?

He holds 63,895 restricted stock units, each representing a right to receive one Ordinary Share upon vesting. These RSUs vest in four equal annual increments on November 26, 2026, 2027, 2028 and 2029, with no stated expiration date, supporting long-term ownership.

Is the exercise price of Marc E. Lippman’s ASCENTAGE PHARMA (AAPG) options in USD or HKD?

The stock options are denominated in HKD, but the reported exercise price of $8.14 reflects a conversion to USD. This conversion uses the exchange rate on the grant date, helping investors understand the option cost in U.S. dollar terms.

Do Marc E. Lippman’s ASCENTAGE PHARMA (AAPG) RSUs have an expiration date?

His 63,895 restricted stock units have no expiration date. They are scheduled to vest in four equal annual tranches on November 26, 2026, 2027, 2028 and 2029, after which each vested RSU converts into one Ordinary Share of the company.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding Insider Trading Forms →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

LIPPMAN MARC E

(Last)

(First)

(Middle)

700 KING FARM BLVD

STE 510

(Street)

ROCKVILLE

MARYLAND

20850

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
03/18/2026

3. Issuer Name and Ticker or Trading Symbol
ASCENTAGE PHARMA GROUP INTERNATIONAL [ AAPG ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Ordinary Shares	21,174	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
1. Title of Derivative Security (Instr. 4)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
Options	⁽¹⁾	11/26/2035	Ordinary Shares	53,895	$8.14⁽²⁾	D
Restricted stock units	⁽³⁾	⁽³⁾	Ordinary Shares	63,895	$0	D

Explanation of Responses:

1. The stock options vest in four equal increments on each of 11/26/2026, 2027, 2028 and 2029.

2. The exercise price for the stock options is in HKD, and the exercise price included in the table represents conversion to USD based on the exchange rate on the date of grant.

3. Each restricted stock unit (RSUs) represents a contingent right to receive one Ordinary Share of the Issuer upon vesting. The RSUs vest in four equal increments on each of 11/26/2026, 2027, 2028 and 2029 and have no expiration date.

Remarks:

	Marc E. Lippman	03/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)

Source: View Original Filing on SEC EDGAR